The four parathyroid glands, through the secretion of parathyroid hormone, regulate serum
calcium concentrations and bone metabolism. 1 In turn, serum calcium concentrations …

Background Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels
in people who have chronic kidney disease (CKD), but the benefits and harms on patient …

Introduction: Chronic kidney disease as a public health problem. Chronic kidney disease is
a worldwide public health problem. In the United States, there is a rising incidence and …

Disturbances in mineral and bone metabolism are common in patients with CKD. A large
body of evidence indicates that these derangements are associated with increased mortality …

Background Treatment of secondary hyperparathyroidism with vitamin D and calcium in
patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia …

Renal osteodystrophy occurs early during loss of kidney function. There are 26 million
American patients with chronic kidney disease (CKD), and almost all patients with CKD …

Chronic kidney disease–mineral bone disorder (CKD‐MBD) is defined by abnormalities in
mineral and hormone metabolism, bone histomorphometric changes, and/or the presence of …

A novel mechanism for skeletal resistance in uremia. Background In treating secondary
hyperparathyroidism, the target level of serum intact parathyroid hormone (I-PTH) should be …

Background. We determined recently that targeted treatment with calcium-based phosphate
binders (calcium acetate and carbonate) led to progressive coronary artery and aortic …

Control of serum phosphate without any phosphate binders in patients treated with nocturnal
hemodialysis. We compared the efficacy and the long-term effects of nocturnal hemodialysis …